A combination of nab-paclitaxel (ABX) and pembrolizumab showed promising results for the treatment of urothelial carcinoma (UC) in prior studies. New findings from the Nure-Combo trial presented by Andrea Necchi, MD, and colleagues at the 2024 American Urological Association Annual Meeting examined the use of ABX with nivolumab followed by radical cystectomy (RC) and adjuvant nivolumab in patients with muscle invasive bladder cancer (MIBC). ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Latest News
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
